Alloantibody toward human leukocyte antigens (HLAs) and blood antigens is a major barrier to successful transplantation. This chapter discusses the current options for transplantation in sensitized renal transplant candidates or those with ABO-incompatible living donors. Specific emphasis is placed on what is known regarding the mechanisms and treatment of both early and late antibody-mediated injury, including the results of some recent therapeutic trials. Finally, current knowledge regarding the mechanism of antibody production in the setting of renal transplantation is outlined, highlighting important gaps in current knowledge in this emerging field.
|Original language||English (US)|
|Title of host publication||Kidney Transplantation - Principles and Practice|
|Number of pages||12|
|State||Published - Jan 1 2019|
- Donor specific antibody
- Kidney transplantation
ASJC Scopus subject areas